Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000276 | 0.84 | FOLH1 (0.53) | FOLH1CA1CA2KMT2A | |
| SCHEMBL27874318 | 0.84 | FOLH1 (0.53) | FOLH1CA1CA2KMT2A | |
| SCHEMBL8562942 | 0.82 | MME (0.43) | CA1CA2 | |
| SCHEMBL8562944 | 0.82 | MME (0.43) | CA1CA2 | |
| SCHEMBL14331615 | 0.82 | CA1 (0.41) | FOLH1CA1CA2 | |
| SCHEMBL14331642 | 0.82 | CA1 (0.41) | FOLH1CA1CA2 | |
| SCHEMBL1998747 | 0.77 | FOLH1 (0.62) | FOLH1 | |
| SCHEMBL12622901 | 0.76 | FOLH1 (0.43) | FOLH1KMT2A | |
| SCHEMBL12622524 | 0.76 | FOLH1 (0.43) | FOLH1KMT2A | |
| SCHEMBL12629379 | 0.76 | FOLH1 (0.43) | FOLH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | PIRAMAL IMAGING SA (CH) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328518-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS | KLK3, FOLH1, ACP3 | FOLH1 2/4885CA1 336/4885CA2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.